Bax upregulation may provide a rationale for the low incidence of esophageal adenocarcinoma in a Greek cohort of patients with Barrett's esophagus

Hepato-Gastroenterology

Volumn 54, Issue 75, 2007, Pages 705-709

  Chatzopoulos, Dimitrios ^a   Kyrgidis, Athanasios ^a   Kountouras, Jannis ^a,b   Zavos, Christos ^a   Molyvas, Epaminondas ^a   Venizelos, Ioannis ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Department of Medicine ^*  (Greece)

Author keywords

Adenocarcinoma; Apoptosis; Barrett's esophagus; Bax; Bcl 2; Ki 67

Indexed keywords

KI 67 ANTIGEN; PROTEIN BAX; PROTEIN BCL 2;

ADULT; APOPTOSIS; ARTICLE; BARRETT ESOPHAGUS; CANCER INCIDENCE; CARCINOGENESIS; CELL PROLIFERATION; COHORT ANALYSIS; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS BIOPSY; ETHNIC DIFFERENCE; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ADENOCARCINOMA; ADULT; APOPTOSIS; BARRETT ESOPHAGUS; BCL-2-ASSOCIATED X PROTEIN; CELL PROLIFERATION; COHORT STUDIES; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; FEMALE; GASTROESOPHAGEAL REFLUX; GREECE; HUMANS; INCIDENCE; KI-67 ANTIGEN; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2; UP-REGULATION;

EID: 34250161576     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. DeMeester SR: Adenocarcinoma of the esophagus and cardia: a review of the disease and its treatment. Ann Surg Oncol 2006; 13:12-30.
2. Pera M, Manterola C, Vidal O, Grande L: Epidemiology of esophageal adenocarcinoma. J Surg Oncol 2005; 92:151-159.
3. Voutilainen ME, Juhola MT: The changing epidemiology of esophageal cancer in Finland and the impact of the surveillance of Barrett's esophagus in detecting esophageal adenocarcinoma. Dis Esophagus 2005; 18:221-225.
4. Farrow DC, Vaughan TL: Determinants of survival following the diagnosis of esophageal adenocarcinoma. Cancer Causes Control 1996; 7:322-327.
5. Garidou A, Tzonou A, Lipworth L, Signorello LB, Kalapothald V, Trichopoulos D: Life-style factors and medical conditions in relation to esophageal cancer by histologic type in a low-risk population. Int J Cancer 1996; 68:295-299.
6. Garidou A, Tzonou A, Lipworth L, Signorello LB, Kalapothald V, Trichopoulos D: Diet and risk of esophageal cancer by histologic type in a low-risk population. Int J Cancer 1996; 68:300-304.
7. Beid BJ, Blount PL, Rubin CE, Levine DS, Haggitt RC, Rabinovitch PS: Flow cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology 1992; 102:1212-1219.
8. Oberg S, Clark GW, DeMeester TR: Barrett's esophagus. Update of pathophysiology and management. Hepatogastroenterology 1998; 45:1348-1356.
9. Khnura H, Konishi K, Jaji M, Maeda K, Yabushita K, Miwa: p53 immunoreactivity in Barrett's metaplasia, dysplasia, and adenocarcinoma-a case report. Hepatogastroenterology 2001; 48:1662-1664.
10. Marsman WA, Tytgat GN, ten Kate FJ, van Lanschot JJ: Differences and similarities of adenocarcinomas of the esophagus and esophagogastric junction. J Surg Oncol 2005; 92:160-168.
11. Irani S, Parkman HP, Thomas R, Krevsky B, Fisher RS, Axelrod P: Increased Barrett's esophagus for the decade between 1991 and 2000 at a single university medical center. Dig Dis Sci 2005; 50:2141-2146.
12. Cameron AJ, Ott BJ, Payne WS: The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med 1985; 313:857-859.
13. Kyrgidis A, Kountouras J, Zavos C, Chatzopoulos D: New molecular concepts of Barrett's esophagus: clinical implications and biomarkers. J Surg Res 2005; 125:189-212.
14. Menke-Pluymers MB, Hop WC, Mulder AH, Tilanus HW: DNA ploidy as a prognostic factor for patients with an adenocarcinoma in Barrett's esophagus. Hepatogastroenterology 1995; 42:786-788.
15. Sanz-Ortega J, Hernandez S, Saez MC, Sierra E, Sanz- Ortega G, Torres A, Balibrea JL, Sanz-Esponera J, Merino MJ: 3p21, 5q21, 9p21 and 17p13.1 allelic deletions are potential markers of individuals with a high risk of developing adenocarcinoma in Barrett's epithelium without dysplasia. Hepatogastroenterology 2003; 50:404-407.
16. Kouklakis GS, Kountouras J, Dokas SM, Molyvas EJ, Vourvoulakis GP, Minopoulos GI: Methylene blue chromoendoscopy for the detection of Barrett's esophagus in a Greek cohort. Endoscopy 2003; 35:383-387.
17. van der Woude CJ, Jansen PL, Tiebosch AT, Beuving A, Homan M, Kleibeuker JH, Moshage H: Expression of apoptosis-related proteins in Barrett's metaplasia-dysplasia-carcinoma sequence: a switch to a more resistant phenotype. Hum Pathol 2002; 33:686-692.
18. Raouf AA, Evoy DA, Carton E, Mulligan E, Griffin MM, Reynolds JV: Loss of Bcl-2 expression in Barrett's dysplasia and adenocarcinoma is associated with tumor progression and worse survival but not with response to neoadjuvant chemoradiation. Dis Esophagus 2003; 16:17-23.
19. Trudgill NJ, Suvarna SK, Royds JA, Riley SA: Cell cycle regulation in patients with intestinal metaplasia at the gastrooesophageal junction. Mol Pathol 2003; 56:313-317.
20. Szachnowicz S, Cecconello I, Iriya K, Marson AG, Takeda FR, Gama-Rodrigues JJ: Origin of adenocarcinoma in Barrett's esophagus: p53 and Ki67 expression and histopathologic background. Clinics 2005; 60:103-112.
21. Kristal AR, Blount PL, Schenk JM, Sanchez CA, Rabi novitch PS, Odze RD, Standley J, Vaughan TL, Reid BJ: Low-fat, high fruit and vegetable diets and weight loss do not affect biomarkers of cellular proliferation in Barrett esophagus. Cancer Epidemiol Biomarkers Prev 2005; 14:2377-2383.
22. Kountouras J, Kouklakis G, Zavos C, Chatzopoulos D, Moschos J, Molyvas E, Zavos N: Apoptosis, inflammatory bowel disease and carcinogenesis: overview of international and Greek experiences. Can J Gastroenterol 2003; 17:249-258.
23. Sturm I, Petrowsky H, Volz R, Lorenz M, Radetzki S, Hillebrand T, Wolff G, Hauptmann S, Dorken B, Daniel PT: Analysis of p53/BAX/p16(ink4a/ CDKN2) in esophageal squamous cell carcinoma: high BAX and p16(ink4a/CDKN2) identifies patients with good prognosis. J Clin Oncol 2001; 19:2272-2281.
24. Kountouras J, Zavos C, Chatzopoulos D: Apoptosis and apoptosis-related proteins in inflammatory bowel disease. Apoptosis 2004; 9:657-658.
25. Kountouras J, Zavos C, Chatzopoulos D: Immunomodulatory benefits of cyclosporine in inflammatory bowel disease. J Cell Mol Med 2004; 8:317-328.
26. Triantafillidis JK, Emmanouilidis A, Manousos ON, Pomonis E, Tsitsa C, Cheracakis P, Barbatzas C: Ulcerative colitis in Greece: clinicoepidemiological data, course, and prognostic factors in 413 consecutive patients. J Clin Gastroenterol 1998; 27:204-210.
27. Katada N, Hinder RA, Smyrk TC, Hirabayashi N, Perdikis G, Lund RJ, Woodward T, Klingler PJ: Apoptosis is inhibited early in the dysplasia-carcinoma sequence of Barrett esophagus. Arch Surg 1997; 132:728-733.
28. Aggarwal S, Taneja N, Lin L, Orringer MB, Rehemtul la A, Beer DG: Indomethacin-induced apoptosis in esophageal adenocarcinoma cells involves upregulation of Bax and translocation of mitochondrial cytochrome C independent of COX-2 expression. Neoplasia 2000; 2:346-356.
29. Hermann S, Sturm I, Mrozek A, Klosterhalfen B, Hauptmann S, Dorken B, Daniel PT: Bax expression in benign and malignant thyroid tumours: dysregulation of wildtype P53 is associated with a high Bax and P21 expression in thyroid carcinoma. Int J Cancer 2001; 92:805-811.
30. Sturm I, Kohne CH, Wolff G, Petrowsky H, Hillebrand T, Hauptmann S, Lorenz M, Dorken B, Daniel PT: Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol 1999; 17:1364-1974.